News for Catalyst Biosciences, Inc. (CBIO)

News for Catalyst Biosciences, Inc.
Date Headline
Apr 12, 2017 04:01 PM Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Apr 11, 2017 08:01 AM Key Milestone Reached in Catalyst’s Subcutaneous Factor IX Program
Apr 07, 2017 11:30 AM Catalyst Biosciences Sinks After Pricing Secondary Offering
Apr 07, 2017 08:30 AM Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
Mar 30, 2017 05:00 PM Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated), Catalyst’s Lead Clinical Program
Mar 30, 2017 09:30 AM Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics
Mar 28, 2017 12:20 PM Why Catalyst Bio Nearly Tripled
Mar 28, 2017 08:01 AM Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program
Mar 21, 2017 09:23 AM Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar 08, 2017 08:20 AM Catalyst Biosciences reports 4Q loss